Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 240.
OPTIRAY 160 vs OPTIRAY 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and organs during imaging procedures.
OPTIRAY 240 (ioversol) is a nonionic, iodinated, water-soluble radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during imaging procedures. Its mechanism is physical: the iodine atoms absorb X-rays, providing radiopacity.
Intravenous: 50-150 mL (total dose 8-30 g iodine) as a bolus or rapid infusion; Intra-arterial: Variable per procedure; maximum 250 mL per procedure.
Intravenous administration: 50-150 mL of OPTIRAY 240 (iopamidol 240 mg iodine/mL) for adult computed tomography (CT) imaging, typically as a bolus or rapid infusion. Dose depends on procedure and patient size.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. Prolonged in renal impairment, up to 20–30 hours in severe renal failure.
Terminal elimination half-life approximately 2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment).
Primarily renal excretion via glomerular filtration; approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Fecal excretion is negligible (<1%).
Primarily renal (glomerular filtration); >90% of administered dose excreted unchanged in urine within 24 hours; <1% biliary/fecal.
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent